Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial) (2018)

Peer-Reviewed Study · Okuno K, Aoyama T, Oba K, Yokoyama N, Matsuhashi N, Kunieda K, Nishimura Y, Akamatsu H, Kobatake T, Morita S, Yoshikawa T, Sakamoto J, Saji S · January 2018

Okuno K et al., 2018-01: JFMC38, a randomised phase III trial of UFT plus PSK versus surgery alone in stage II rectal cancer, closed early at 20% of planned accrual. Five-year disease-free survival was numerically worse with UFT plus PSK (65.1% vs 77.2%, p = 0.102) and the authors judged the regimen not worth advancing.

The present study suggests that UFT and PSK are not attractive candidates to advance to the next phase III study because the DFS was slightly worse in the UFT and PSK arm than in the surgery-alone arm.

Abstract, Results and Conclusion

Okuno K et al., 2018-01: JFMC38, a randomised phase III trial of UFT plus PSK versus surgery alone in stage II rectal cancer, closed early at 20% of planned accrual. Five-year disease-free survival was numerically worse with UFT plus PSK (65.1% vs 77.2%, p = 0.102) and the authors judged the regimen not worth advancing. Underpowered by design failure (111 of ~550 planned patients), so the negative result is not decisive against PSK, but it is the most recent randomised colorectal test and it did not replicate the older meta-analysis. Conflict: Satoshi Morita 'has received remuneration entity from Taiho and Daiichi-Sankyo'. Comparator: surgery alone. Study type: randomized trial.